National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Imatinib mesylate(IM) is the most commonly used drug for therapy of chronic myeloid leukemia (CML). It exerts its effect by targeting a constitutively activated tyrosine kinase Bcr-Abl, a characteristic feature of CML. This anti-tumor drug also influences various other proteins like cytokines, transcription factors and their associated signalling pathways that contribute to the development of leukemogenesis. However, it poses serious side effects. Thus attention should be given to non-toxic means of leukemia control. Phytochemicals like curcumin possess a plethora of anti-cancer properties, show minimal toxicity and may therefore come to the rescue. The present study aims to explore the potential of curcumin to boost up the efficacy of IM, and to minimize the drug dose and associated toxicity in human chronic myelogenous leukemia cell line K-562. The drug IM was found to modulate the expression of markers deregulated in CML. However, curcumin refines the efficacy of IM, especially when added prior to drug treatment. Similar trend was reflected in induction of programmed cell death. Thus the phytochemical curcumin may enhance the potency of IM used in leukemia therapy, thereby suggesting its role in an adjuvant therapy for CML.
Citations |
 |
 |
 |
 |
